BSH 2017 | Managing and predicting TLS in CLL patients

Peter Hillmen

Peter Hillmen, MBChB, PhD, FRCP, FRCPath from Leeds Teaching Hospital NHS Trust, Leeds, UK speaks about the use of venetoclax in chronic lymphocytic leukemia (CLL), and the associated risk of tumor lysis syndrome (TLS). Venetoclax causes rapid apoptosis of cells after administration, which can lead to a high volume of chemicals in the body, developing into TLS. TLS can be life-threatening if it is not managed properly so clinicians need to be extremely careful and not be complacent when making the appropriate observations. This interview was recorded at the 2017 British Society for Hematology (BSH) Annual Scientific Meeting in Brighton, UK. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.

Share this video